Cisplatin-Induced Kidney Injury: Comparison
View Latest Version
Please note this is a comparison between Version 3 by Rita Xu and Version 2 by Peter Tang.

Cisplatin is a chemotherapy agent commonly used to treat a wide variety of cancers. Despite the potential for both severe acute and chronic side effects, it remains a preferred therapeutic option for many malignancies due to its potent anti-tumor activity. Common cisplatin-associated side-effects include acute kidney injury (AKI) and chronic kidney disease (CKD). These renal injuries may cause delays and potentially cessation of cisplatin therapy and have long-term effects on renal function reserve. Thus, developing mechanism-based interventional strategies that minimize cisplatin-associated kidney injury without reducing efficacy would be of great benefit. In addition to its action of cross-linking DNA, cisplatin has been shown to affect mitochondrial metabolism, resulting in mitochondrially derived reactive oxygen species (ROS). Increased ROS formation in renal proximal convoluted tubule cells is associated with cisplatin-induced AKI and CKD. We review the mechanisms by which cisplatin may induce AKI and CKD and discuss the potential of mitochondrial superoxide dismutase mimetics to prevent platinum-associated nephrotoxicity.

  • superoxide dismutase
  • mitochondria
  • reactive oxygen species
  • mitochondrial metabolism
  • superoxide
Please wait, diff process is still running!

References

  1. Rosenberg, B.; VanCamp, L.; Trosko, J.E.; Mansour, V.H. Platinum compounds: A new class of potent antitumour agents. Nature 1969, 222, 385–386.
  2. Higby, D.J.; Wallace, H.J., Jr.; Albert, D.; Holland, J.F. Diamminodichloroplatinum in the chemotherapy of testicular tumors. J. Urol. 1974, 112, 100–104.
  3. Einhorn, L.H.; Donohue, J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med. 1977, 87, 293–298.
  4. Wiltshaw, E.; Subramarian, S.; Alexopoulos, C.; Barker, G.H. Cancer of the ovary: A summary of experience with cis-dichlorodiammineplatinum(II) at the Royal Marsden Hospital. Cancer Treat. Rep. 1979, 63, 1545–1548.
  5. Chan, D.C. Mitochondrial fusion and fission in mammals. Annu. Rev. Cell Dev. Biol. 2006, 22, 79–99.
  6. Prestayko, A.W.; D’Aoust, J.C.; Issell, B.F.; Crooke, S.T. Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat. Rev. 1979, 6, 17–39.
  7. Rosenberg, B.; VanCamp, L. The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res. 1970, 30, 1799–1802.
  8. Harder, H.C.; Rosenberg, B. Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in virtro. Int. J. Cancer 1970, 6, 207–216.
  9. Howle, J.A.; Gale, G.R. Cis-dichlorodiammineplatinum (II). Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. Biochem. Pharmacol. 1970, 19, 2757–2762.
  10. Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4, 307–320.
  11. Alvarez, M.V.; Cobreros, G.; Heras, A.; Lopez Zumel, M.C. Studies on cis-dichlorodiammineplatinum (II) as a radiosensitizer. Br. J. Cancer Suppl. 1978, 3, 68–72.
  12. Al-Sarraf, M.; Pajak, T.F.; Marcial, V.A.; Mowry, P.; Cooper, J.S.; Stetz, J.; Ensley, J.F.; Velez-Garcia, E. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG Study. Cancer 1987, 59, 259–265.
  13. Schaake-Koning, C.; van den Bogaert, W.; Dalesio, O.; Festen, J.; Hoogenhout, J.; van Houtte, P.; Kirkpatrick, A.; Koolen, M.; Maat, B.; Nijs, A.; et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med. 1992, 326, 524–530.
  14. Rose, P.G.; Bundy, B.N.; Watkins, E.B.; Thigpen, J.T.; Deppe, G.; Maiman, M.A.; Clarke-Pearson, D.L.; Insalaco, S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 1999, 340, 1144–1153.
  15. Forastiere, A.A.; Goepfert, H.; Maor, M.; Pajak, T.F.; Weber, R.; Morrison, W.; Glisson, B.; Trotti, A.; Ridge, J.A.; Chao, C.; et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 2003, 349, 2091–2098.
  16. Maddalo, M.; Borghetti, P.; Tomasini, D.; Corvo, R.; Bonomo, P.; Petrucci, A.; Paiar, F.; Lastrucci, L.; Bonu, M.L.; Greco, D.; et al. Cetuximab and Radiation Therapy Versus Cisplatin and Radiation Therapy for Locally Advanced Head and Neck Cancer: Long-Term Survival and Toxicity Outcomes of a Randomized Phase 2 Trial. Int. J. Radiat. Oncol. Biol. Phys. 2020, 107, 469–477.
  17. Adelstein, D.J.; Li, Y.; Adams, G.L.; Wagner, H., Jr.; Kish, J.A.; Ensley, J.F.; Schuller, D.E.; Forastiere, A.A. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 2003, 21, 92–98.
  18. Faig, J.; Haughton, M.; Taylor, R.C.; D’Agostino, R.B., Jr.; Whelen, M.J.; Porosnicu Rodriguez, K.A.; Bonomi, M.; Murea, M.; Porosnicu, M. Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy. Am. J. Clin. Oncol. 2018, 41, 432–440.
  19. Ameri, A.; Norouzi, S.; Sourati, A.; Azghandi, S.; Novin, K.; Taghizadeh-Hesary, F. Randomized trial on acute toxicities of weekly vs three-weekly cisplatin-based chemoradiation in head and neck cancer. Cancer Rep. 2021, e1425.
  20. Reece, P.A.; Stafford, I.; Russell, J.; Khan, M.; Gill, P.G. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J. Clin. Oncol. 1987, 5, 304–309.
  21. Kemp, G.; Rose, P.; Lurain, J.; Berman, M.; Manetta, A.; Roullet, B.; Homesley, H.; Belpomme, D.; Glick, J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol. 1996, 14, 2101–2112.
  22. Latcha, S.; Jaimes, E.A.; Patil, S.; Glezerman, I.G.; Mehta, S.; Flombaum, C.D. Long-Term Renal Outcomes after Cisplatin Treatment. Clin. J. Am. Soc. Nephrol. 2016, 11, 1173–1179.
  23. Stark, J.J.; Howel, S.B. Nephrotoxicity of cis-platinum (II) dichlorodiammine. Clin. Pharmacol. Ther. 1978, 23, 461–466.
  24. Kang, M.H.; Kang, J.H.; Song, H.N.; Jeong, B.K.; Chai, G.Y.; Kang, K.; Woo, S.H.; Park, J.J.; Kim, J.P. Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma. Cancer Res. Treat. 2015, 47, 441–447.
  25. Rossi, A.; Di Maio, M.; Chiodini, P.; Rudd, R.M.; Okamoto, H.; Skarlos, D.V.; Fruh, M.; Qian, W.; Tamura, T.; Samantas, E.; et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. J. Clin. Oncol. 2012, 30, 1692–1698.
  26. Liu, Y.H.; Li, K.; Tian, H.Q. Renoprotective Effects of a New Free Radical Scavenger, XH-003, against Cisplatin-Induced Nephrotoxicity. Oxid. Med. Cell Longev. 2020, 2020, 9820168.
  27. Capizzi, R.L. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: Laboratory and clinical aspects. Semin. Oncol. 1999, 26 (Suppl. 7), 72–81.
  28. Tannehill, S.P.; Mehta, M.P.; Larson, M.; Storer, B.; Pellet, J.; Kinsella, T.J.; Schiller, J.H. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: Results of a phase II trial. J. Clin. Oncol. 1997, 15, 2850–2857.
  29. Koukourakis, M.I.; Giatromanolaki, A.; Zois, C.E.; Kalamida, D.; Pouliliou, S.; Karagounis, I.V.; Yeh, T.L.; Abboud, M.I.; Claridge, T.D.; Schofield, C.J.; et al. Normal tissue radioprotection by amifostine via Warburg-type effects. Sci. Rep. 2016, 6, 30986.
  30. Benoehr, P.; Krueth, P.; Bokemeyer, C.; Grenz, A.; Osswald, H.; Hartmann, J.T. Nephroprotection by theophylline in patients with cisplatin chemotherapy: A randomized, single-blinded, placebo-controlled trial. J. Am. Soc. Nephrol. 2005, 16, 452–458.
  31. Yao, K.; Kusaka, H.; Sano, J.; Sato, K.; Karasawa, A. Diuretic effects of KW-3902, a novel adenosine A1-receptor antagonist, in various models of acute renal failure in rats. Jpn. J. Pharmacol. 1994, 64, 281–288.
  32. Winston, J.A.; Safirstein, R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am. J. Physiol. 1985, 249, F490–F496.
  33. Levey, A.S.; Eckardt, K.U.; Tsukamoto, Y.; Levin, A.; Coresh, J.; Rossert, J.; De Zeeuw, D.; Hostetter, T.H.; Lameire, N.; Eknoyan, G. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005, 67, 2089–2100.
  34. Chawla, L.S.; Bellomo, R.; Bihorac, A.; Goldstein, S.L.; Siew, E.D.; Bagshaw, S.M.; Bittleman, D.; Cruz, D.; Endre, Z.; Fitzgerald, R.L.; et al. Acute kidney disease and renal recovery: Consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat. Rev. Nephrol. 2017, 13, 241–257.
  35. Motwani, S.S.; McMahon, G.M.; Humphreys, B.D.; Partridge, A.H.; Waikar, S.S.; Curhan, G.C. Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin. J. Clin. Oncol. 2018, 36, 682–688.
  36. Section 2: AKI Definition. Kidney Int. Suppl. (2011) 2012, 2, 19–36.
  37. Hansen, S.W.; Groth, S.; Daugaard, G.; Rossing, N.; Rorth, M. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J. Clin. Oncol. 1988, 6, 1728–1731.
  38. Gaut, J.P.; Liapis, H. Acute kidney injury pathology and pathophysiology: A retrospective review. Clin. Kidney J. 2021, 14, 526–536.
  39. Pabla, N.; Dong, Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 2008, 73, 994–1007.
  40. Oh, G.S.; Kim, H.J.; Shen, A.; Lee, S.B.; Yang, S.H.; Shim, H.; Cho, E.Y.; Kwon, K.B.; Kwak, T.H.; So, H.S. New Therapeutic Concept of NAD Redox Balance for Cisplatin Nephrotoxicity. Biomed. Res. Int. 2016, 2016, 4048390.
  41. Hamroun, A.; Lenain, R.; Bigna, J.J.; Speyer, E.; Bui, L.; Chamley, P.; Pottier, N.; Cauffiez, C.; Dewaeles, E.; Dhalluin, X.; et al. Prevention of Cisplatin-Induced Acute Kidney Injury: A Systematic Review and Meta-Analysis. Drugs 2019, 79, 1567–1582.
  42. Mapuskar, K.A.; Wen, H.; Holanda, D.G.; Rastogi, P.; Steinbach, E.; Han, R.; Coleman, M.C.; Attanasio, M.; Riley, D.P.; Spitz, D.R.; et al. Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease. Redox Biol. 2019, 20, 98–106.
  43. Singh, G. A possible cellular mechanism of cisplatin-induced nephrotoxicity. Toxicology 1989, 58, 71–80.
  44. Zhang, L.; Cooper, A.J.; Krasnikov, B.F.; Xu, H.; Bubber, P.; Pinto, J.T.; Gibson, G.E.; Hanigan, M.H. Cisplatin-induced toxicity is associated with platinum deposition in mouse kidney mitochondria in vivo and with selective inactivation of the alpha-ketoglutarate dehydrogenase complex in LLC-PK1 cells. Biochemistry 2006, 45, 8959–8971.
  45. Mukhopadhyay, P.; Horvath, B.; Zsengeller, Z.; Zielonka, J.; Tanchian, G.; Holovac, E.; Kechrid, M.; Patel, V.; Stillman, I.E.; Parikh, S.M.; et al. Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radic. Biol. Med. 2012, 52, 497–506.
  46. Zsengeller, Z.K.; Ellezian, L.; Brown, D.; Horvath, B.; Mukhopadhyay, P.; Kalyanaraman, B.; Parikh, S.M.; Karumanchi, S.A.; Stillman, I.E.; Pacher, P. Cisplatin nephrotoxicity involves mitochondrial injury with impaired tubular mitochondrial enzyme activity. J. Histochem. Cytochem. 2012, 60, 521–529.
  47. Cooper, A.J.; Krasnikov, B.F.; Niatsetskaya, Z.V.; Pinto, J.T.; Callery, P.S.; Villar, M.T.; Artigues, A.; Bruschi, S.A. Cysteine S-conjugate beta-lyases: Important roles in the metabolism of naturally occurring sulfur and selenium-containing compounds, xenobiotics and anticancer agents. Amino Acids 2011, 41, 7–27.
  48. Hanigan, M.H.; Lykissa, E.D.; Townsend, D.M.; Ou, C.N.; Barrios, R.; Lieberman, M.W. Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. Am. J. Pathol. 2001, 159, 1889–1894.
  49. Townsend, D.M.; Deng, M.; Zhang, L.; Lapus, M.G.; Hanigan, M.H. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J. Am. Soc. Nephrol. 2003, 14, 1–10.
  50. Zhang, L.; Hanigan, M.H. Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin. J. Pharmacol. Exp. Ther. 2003, 306, 988–994.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback